Autoradiographic mapping of synaptic vesicle glycoprotein 2A in non-human primate and human brain.
Adult
Animals
Brain
/ growth & development
Female
Gray Matter
/ diagnostic imaging
Humans
Macaca fascicularis
Male
Membrane Glycoproteins
/ metabolism
Middle Aged
Nerve Tissue Proteins
/ metabolism
Positron-Emission Tomography
Protein Binding
Pyridines
/ pharmacokinetics
Pyrrolidines
/ pharmacokinetics
Radiopharmaceuticals
/ pharmacokinetics
White Matter
/ diagnostic imaging
PET radioligands
[11C]UCB-J
autoradiography
brain imaging
primate brain
synaptic density
synaptic vesicle glycoprotein 2A
Journal
Synapse (New York, N.Y.)
ISSN: 1098-2396
Titre abrégé: Synapse
Pays: United States
ID NLM: 8806914
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
04
03
2020
revised:
25
03
2020
accepted:
30
03
2020
pubmed:
8
4
2020
medline:
11
8
2021
entrez:
8
4
2020
Statut:
ppublish
Résumé
Synaptic vesicle glycoprotein 2A (SV2A) has been previously characterized as an imaging biomarker for assessment of synaptic density in positron emission tomography (PET) studies of patients with neurological conditions. To provide detailed maps of the brain localization of SV2A autoradiography studies were carried out using the SV2A radioligand [
Substances chimiques
(11c)-ucb
0
Membrane Glycoproteins
0
Nerve Tissue Proteins
0
Pyridines
0
Pyrrolidines
0
Radiopharmaceuticals
0
SV2A protein, human
148845-93-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e22157Informations de copyright
© 2020 The Authors. Synapse published by Wiley Periodicals LLC.
Références
Bajjalieh, S. M., Frantz, G. D., Weimann, J. M., McConnell, S. K., & Scheller, R. H. (1994). Differential expression of synaptic vesicle protein 2 (SV2) isoforms. Journal of Neuroscience, 14, 5223-5235. https://doi.org/10.1523/jneurosci.14-09-05223.1994
Chen, M.-K., Mecca, A. P., Naganawa, M., Finnema, S. J., Toyonaga, T., Lin, S.-F., … van Dyck, C. H. (2018). Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurology, 75, 1215-1224. https://doi.org/10.1001/jamaneurol.2018.1836
Davies, K. G., Schweitzer, J. B., Looney, M. R., Bush, A. J., Dohan, F. C., & Hermann, B. P. (1998). Synaptophysin immunohistochemistry densitometry measurement in resected human hippocampus: Implication for the etiology of hippocampal sclerosis. Epilepsy Research, 32, 335-344. https://doi.org/10.1016/S0920-1211(98)00032-1
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., … Carson, R. E. (2016). Imaging synaptic density in the living human brain. Science Translational Medicine, 8(348), 348ra96. https://doi.org/10.1126/scitranslmed.aaf6667
Finnema, S. J., Nabulsi, N. B., Mercier, J., Lin, S. F., Chen, M. K., Matuskey, D., … Carson, R. E. (2018). Kinetic evaluation and test-retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. Journal of Cerebral Blood Flow and Metabolism, 38, 2041-2052. https://doi.org/10.1177/0271678X17724947
Hall, H., Halldin, C., Farde, L., & Sedvall, G. (1998). Whole hemisphere autoradiography of the postmortem human brain. Nuclear Medicine and Biology, 25, 715-719. https://doi.org/10.1016/S0969-8051(98)00053-5
Heurling, K., Ashton, N. J., Leuzy, A., Zimmer, E. R., Blennow, K., Zetterberg, H., … Schöll, M. (2019). Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. Molecular and Cellular Neuroscience, 97, 34-42. https://doi.org/10.1016/j.mcn.2019.02.001
Koole, M., van Aalst, J., Devrome, M., Mertens, N., Serdons, K., Lacroix, B., … Van Laere, K. (2019). Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue. European Journal of Nuclear Medicine and Molecular Imaging, 46, 396-406. https://doi.org/10.1007/s00259-018-4119-8
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016). Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond. CNS Drugs, 30, 1055-1077. https://doi.org/10.1007/s40263-016-0384-x
Matuskey, D., Tinaz, S., Wilcox, K. C., Naganawa, M., Toyonaga, T., Dias, M., … Carson, R. E. (2020). Synaptic changes in Parkinson's disease assessed with in-vivo imaging. Annals of Neurology, 87, 329-338. https://doi.org/10.1002/ana.25682
Mendoza-Torreblanca, J. G., García-Cruz, M. E., Sánchez-Cruz, I., Gomez-Gonzalez, B., Juárez-Méndez, S., & Gómez-Lira, G. (2019). Analysis of differential expression of synaptic vesicle protein 2A in the adult rat brain. Neuroscience, 419, 108-120. https://doi.org/10.1016/j.neuroscience.2019.09.004
Mercier, J., Provins, L., & Valade, A. (2017). Discovery and development of SV2A PET tracers: Potential for imaging synaptic density and clinical applications. Drug Discovery Today: Technologies, 25, 45-52. https://doi.org/10.1016/j.ddtec.2017.11.003
Nabulsi, N. B., Mercier, J., Holden, D., Carre, S., Najafzadeh, S., Vandergeten, M.-C., … Huang, Y. (2016). Synthesis and preclinical evaluation of 11C-UCB-J as a PET tracer for imaging the synaptic vesicle glycoprotein 2A in the brain. Journal of Nuclear Medicine, 57, 777-784. https://doi.org/10.2967/jnumed.115.168179
Nowack, A., Yao, J., Custer, K. L., & Bajjalieh, S. M. (2010). SV2 regulates neurotransmitter release via multiple mechanisms. American Journal of Physiology - Cell Physiology, 299, C960-C967. https://doi.org/10.1152/ajpcell.00259.2010
Ohno, Y., Okumura, T., Terada, R., Ishihara, S., Serikawa, T., & Sasa, M. (2012). Kindling-associated SV2A expression in hilar GABAergic interneurons of the mouse dentate gyrus. Neuroscience Letters, 510, 93-98. https://doi.org/10.1016/j.neulet.2012.01.009
Onwordi, E. C., Halff, E. F., Whitehurst, T., Mansur, A., Cotel, M.-C., Wells, L., … Howes, O. D. (2020). Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nature Communications, 11, 246. https://doi.org/10.1038/s41467-019-14122-0
Patel, S., Knight, A., Krause, S., Teceno, T., Tresse, C., Li, S., … Passchier, J. (2019). Preclinical in vitro and in vivo characterization of synaptic vesicle 2A-targeting compounds amenable to F-18 labeling as potential PET radioligands for imaging of synapse integrity. Molecular Imaging and Biology. https://doi.org/10.1007/s11307-019-01428-0
Rossano, S., Toyonaga, T., Finnema, S. J., Naganawa, M., Lu, Y., Nabulsi, N., … Carson, R. E. (2019). Assessment of a white matter reference region for 11C-UCB-J PET quantification. Journal of Cerebral Blood Flow and Metabolism. https://doi.org/10.1177/0271678X19879230
Sinjab, B., Martinian, L., Sisodiya, S. M., & Thom, M. (2013). Regional thalamic neuropathology in patients with hippocampal sclerosis and epilepsy: A postmortem study. Epilepsia, 54, 2125-2133. https://doi.org/10.1111/epi.12403
Stout, K. A., Dunn, A. R., Hoffman, C., & Miller, G. W. (2019). The synaptic vesicle glycoprotein 2: Structure, function, and disease relevance. ACS Chemical Neuroscience, 10, 3927-3938. https://doi.org/10.1021/acschemneuro.9b00351
Van Vliet, E. A., Aronica, E., Redeker, S., Boer, K., & Gorter, J. A. (2009). Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia, 50, 422-433. https://doi.org/10.1111/j.1528-1167.2008.01727.x
Vanoye-Carlo, A., & Gómez-Lira, G. (2019). Differential expression of SV2A in hippocampal glutamatergic and GABAergic terminals during postnatal development. Brain Research, 1715, 73-83. https://doi.org/10.1016/j.brainres.2019.03.021
Wan, Q. F., Zhou, Z. Y., Thakur, P., Vila, A., Sherry, D. M., Janz, R., & Heidelberger, R. (2010). SV2 acts via presynaptic calcium to regulate neurotransmitter release. Neuron, 66, 884-895. https://doi.org/10.1016/j.neuron.2010.05.010